✨ Free AI Report
Q32 Bio Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Q32 Bio Inc.
Company Research

Q32 Bio Inc.: Business Overview, Financials & Competitive Analysis

Q32 Bio is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The co...

Analyst-debate audio for Q32 Bio Inc.

AskCyborg analysts argue the bull and bear cases for Q32 Bio Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Highly speculative clinical-stage biotech play dependent on mid-2026 Phase 2 data readout for lead candidate bempikibart in...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunology & Inflammation (Biopharmaceuticals)
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Q32 Bio Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Q32 Bio Inc. Overview

Pro stress-test →

Q32 Bio is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program.

Strategic Profile

Pro stress-test →

Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront and near-term payments, eligible for up to $592 million in total milestone payments plus tiered royalties. This transaction extends the company's cash runway into the second half of 2027 while it advances bempikibart, with SIGNAL-AA Part B topline data on track for mid-2026.

Competitive Landscape

Pro stress-test →

Q32 Bio competes in the alopecia areata therapeutics space, an emerging category with limited approved treatments. The company's main focus is bempikibart for atopic dermatitis and alopecia areata, with a supporting complement platform including ADX-096 for ophthalmologic indications. Competitors include other immunology-focused biotech companies pursuing immune rebalancing approaches.

Industry Context

Q32 Bio Inc. operates in Biotechnology - Immunology & Inflammation (Biopharmaceuticals).

Key facts

Founded: 2017 · Headquarters: Waltham, Massachusetts, US · Employees: 42 · Revenue: N/A · Market cap: $52.5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Q32 Bio Inc..

  • Q32 Bio completed enrollment in Part B of the SIGNAL-AA Phase 2a trial and increased the cohort to 33 patients, with topline data expected in mid-2026.
  • The company received Fast Track designation for bempikibart, indicating FDA recognition of the unmet medical need.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2026Management to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
  • Dec 2025Sold Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12M upfront plus up to $592M in milestone payments
  • +1 moreTrack every material event for Q32 Bio Inc. as it happens. Explore monitoring →
Get alerted when Q32 Bio Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

JAK inhibitors (topical)Approved treatments for alopecia areata; established but with tolerability concerns→Dupilumab and similar biologicsImmunomodulatory therapies being explored for alopecia areata→Other IL-7R antagonists in developmentSimilar mechanism of action targeting adaptive immune pathways→

Compare Q32 Bio Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Q32 Bio Inc. operates in Biotechnology - Immunology & Inflammation (Biopharmaceuticals). See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunology & Inflammation (Biopharmaceuticals) research →
NEW · MCP server

Ask your AI assistant about Q32 Bio Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Q32 Bio Inc. and its top competitor on Cyborg Score”
“What did Q32 Bio Inc. do this quarter?”
“Is Q32 Bio Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Q32 Bio Inc. do?+
Q32 Bio is a clinical-stage biotechnology company that develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The co...
What is Q32 Bio Inc.'s Cyborg Score?+
Q32 Bio Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Q32 Bio Inc.'s main competitors?+
Named competitors include JAK inhibitors (topical), Dupilumab and similar biologics, Other IL-7R antagonists in development. The full competitive landscape is in the AskCyborg report.
How can I get the full Q32 Bio Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Q32 Bio Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Q32 Bio Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.